A Atrofia Dentatorrubral-Palidoluisiana (DRPLA) é um tipo raro de ataxia cerebelar autossômica dominante tipo I (ADCA tipo I). Trata-se de uma doença neurológica hereditária, que afeta o cerebelo (a parte do cérebro responsável pelo equilíbrio e pela coordenação dos movimentos), sendo transmitida de forma dominante. Os sintomas incluem movimentos involuntários, dificuldade de coordenação (ataxia), crises epilépticas, problemas de saúde mental (como alterações de humor e comportamento), perda da capacidade de pensar e memorizar, e uma característica peculiar chamada "antecipação proeminente", onde a doença tende a surgir mais cedo e/ou com mais gravidade a cada nova geração da família.
Introdução
O que você precisa saber de cara
A Atrofia Dentatorrubral-Palidoluisiana (DRPLA) é um tipo raro de ataxia cerebelar autossômica dominante tipo I (ADCA tipo I). Trata-se de uma doença neurológica hereditária, que afeta o cerebelo (a parte do cérebro responsável pelo equilíbrio e pela coordenação dos movimentos), sendo transmitida de forma dominante. Os sintomas incluem movimentos involuntários, dificuldade de coordenação (ataxia), crises epilépticas, problemas de saúde mental (como alterações de humor e comportamento), perda da capacidade de pensar e memorizar, e uma característica peculiar chamada "antecipação proeminente", onde a doença tende a surgir mais cedo e/ou com mais gravidade a cada nova geração da família.
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 21 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 38 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.
Transcriptional corepressor. Recruits NR2E1 to repress transcription. Promotes vascular smooth cell (VSMC) migration and orientation (By similarity). Corepressor of MTG8 transcriptional repression. Has some intrinsic repression activity which is independent of the number of poly-Gln (polyQ) repeats
NucleusCytoplasm, perinuclear regionCell junction
Dentatorubral-pallidoluysian atrophy
Autosomal dominant neurodegenerative disorder characterized by a loss of neurons in the dentate nucleus, rubrum, glogus pallidus and Luys'body. Clinical features are myoclonus epilepsy, dementia, and cerebellar ataxia. Onset of the disease occurs usually in the second decade of life and death in the fourth.
Variantes genéticas (ClinVar)
91 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 15 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
1 via biológica associada aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Atrofia dentato-rubro-pálido-luisiana
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
5 ensaios clínicos encontrados, 4 ativos.
Publicações mais relevantes
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
Dentatorubral-pallidoluysian atrophy (DRPLA) is a fatal neurodegenerative disease arising from a CAG repeat expansion in the atrophin-1 (ATN1) gene. Because DRPLA, like many repeat expansion disorders (REDs), arises predominantly from toxic gain-of-function mechanisms, we hypothesized that ATN1 knockdown would have therapeutic potential. To test this, we established the first fully humanized mouse model of a RED, in which one allele of mouse Atn1 is completely replaced by human ATN1, including 112 pure CAG repeats. This novel approach to exploring RED biology provides significant advantages, notably the ability to test sequence-specific therapeutics targeting human sequences, even in introns and untranslated regions of pre-mRNA. We found that our model-the Atn1 Q112/+ mouse-recapitulates key features of human DRPLA, including behavioral alterations, reduced brain size, and aggregate accumulation. We treated Atn1 Q112/+ mice with antisense oligonucleotides (ASOs) targeting mouse Atn1 (to probe for loss of function concerns), human ATN1, or a combination. Treatment with human, but not mouse, ATN1-targeting ASOs provides remarkable protection from a range of disease-related behavioral phenotypes and marked rescue of transcriptional dysregulation in the cerebellum. These results have helped motivate an ongoing human clinical study of ASOs targeting ATN1 for DRPLA.
Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review.
Hereditary ataxias are a heterogeneous group of disorders with overlapping clinical presentations but diverse genetic and molecular etiologies. Biomarkers are increasingly essential to improve diagnosis, refine prognosis, and accelerate the development of targeted therapies. Following PRISMA-ScR guidelines, we conducted a scoping review of PubMed and complementary sources (2010-2025) to map and describe the current landscape of genetic, imaging, fluid, electrophysiological, and digital biomarkers across the most prevalent hereditary ataxias, including SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, SCA27B, dentatorubral-pallidoluysian atrophy (DRPLA), Friedreich's ataxia (FRDA), RFC1-related ataxia (CANVAS), SPG7, and fragile X-associated tremor/ataxia syndrome (FXTAS). Eligible evidence encompassed observational cohorts, clinical trials, case series, and case reports providing primary biomarker data, with the objective of characterizing evidence breadth and identifying knowledge gaps rather than assessing comparative effectiveness. Across modalities, converging evidence highlights subtype-specific biomarker signatures. MRI volumetry, DTI, and FDG-PET map characteristic neurodegeneration patterns. Fluid biomarkers such as neurofilament light chain are informative across several SCAs and FRDA, while frataxin levels constitute robust endpoints in FRDA trials. Pathology-specific biomarkers such as ataxin-3 are advancing as tools for target engagement and may generalize to future gene-lowering strategies. Electrophysiological and oculographic measures show sensitivity for early disease detection, and wearable technologies are emerging as scalable tools for longitudinal monitoring. This scoping review synthesizes the heterogeneous evidence on hereditary ataxia biomarkers, highlighting multimodal frameworks that link molecular mechanisms with clinical endpoints. Mapping current approaches also reveals substantial variability and gaps across diseases and modalities, underscoring the need for harmonized validation in international multicenter cohorts and systematic integration into future clinical trials to advance precision medicine in hereditary ataxias.
Long-term efficacy and disease-specific responsiveness to protirelin in patients with spinocerebellar degeneration: A retrospective study.
The thyrotropin-releasing hormone (TRH) analog protirelin has short-term benefits for cerebellar ataxia (CA), but its long-term efficacy and the subtype-specific responsiveness of spinocerebellar degeneration (SCD) patients remain unclear. We retrospectively reviewed the records of 92 SCD patients (273 courses) treated with protirelin between July 2011 and October 2025, including patients with idiopathic CA (IDCA), multiple system atrophy with predominant CA (MSA-C) or parkinsonism (MSA-P), and genetic subtypes including spinocerebellar ataxia (SCA) type 6, SCA31 and dentatorubral-pallidoluysian atrophy (DRPLA). Responders were defined as showing ≥1-point improvement on the Scale for the Assessment and Rating of Ataxia (SARA). Protirelin was effective in 64.1% of subjects, with significant improvement overall (p < 0.001) and significant SARA gains in MSA-C (p = 0.047), IDCA (p = 0.02), and SCA31 (p = 0.01). Change in SARA score (ΔSARA) correlated negatively with age and positively with total protirelin dose in IDCA, and negatively with age and disease duration and positively with baseline SARA score in SCA31. Several IDCA and DRPLA patients maintained clinical benefit for more than 10 years. All MSA-P discontinued protirelin within 2 years and all MSA-C within 5 years; some SCA6, and SCA31 patients continued for ≥5 years. Adverse effects were infrequent (2/92, 2.2%). Protirelin is efficacious in SCD patients and well-tolerated, particularly in slow-progressing phenotypes (IDCA and SCA31); its benefit in rapidly progressing ataxias (MSA-C) may be confined to early disease stages. Prospective studies with standardized dosing and long-term follow-up are warranted to establish evidence-based protocols for TRH-related therapy for CA.
[Trinucleotide repeat disorders].
Trinucleotide disorders are a heterogeneous group that lead to neurodegeneration with severe motor and psychiatric impairments. Neither the clinical presentation nor the radiological signs are specific, leading to frequent misdiagnoses. Neuroradiological signs in trinucleotide disorders. A search in pubmed.gov was conducted to identify studies reflecting the current state of knowledge. An overview of the most common trinucleotide disorders and their characteristic radiological features is provided. As in many degenerative diseases, imaging represents only one piece of the puzzle and primarily provides guidance as to the diagnostic direction. HINTERGRUND: Trinukleotid-Erkrankungen sind eine heterogene Gruppe, die zur Neurodegeneration mit schweren motorischen und psychischen Einschränkungen führen. Weder die Klinik noch die radiologischen Zeichen sind eindeutig, weshalb es häufig zu Fehldiagnosen kommt. Neuroradiologische Veränderungen bei Trinukleotid-Erkrankungen. Eine pubmed.gov-Suche nach Studien wurde durchgeführt, um den aktuellen Wissensstand widerzuspiegeln. Es erfolgt eine Übersicht über die häufigsten Trinukleotid-Erkrankungen sowie deren radiologischen Besonderheiten. Wie bei vielen degenerativen Erkrankungen ist die Bildgebung nur ein Teil des Puzzles und gibt einen Hinweis, in welche Richtung die Reise geht.
ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.
The neuregulin-ERBB4 pathway is essential for maintaining cellular function. Upon stimulation by its ligand, neuregulin, ERBB4-a receptor tyrosine kinase-triggers multiple cellular responses, including proliferation, apoptosis, differentiation, and neuromuscular junction formation. Previous research has implicated dysregulated ERBB4 signaling in the pathophysiology of several neurodegenerative disorders, such as Alzheimer's disease, progressive supranuclear palsy, amyotrophic lateral sclerosis, and Parkinson's disease. In this study, we examined ERBB4 expression in diseases characterized by phosphorylated tau (MAPT) pathology. We found that ERBB4 colocalized with neuronal and glial phosphorylated tau-positive inclusions in multiple tauopathies, including Pick's disease, Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, argyrophilic grain disease, and frontotemporal lobar degeneration with MAPT mutation. Conversely, ERBB4 did not colocalize with α-synuclein aggregates in α-synucleinopathies (Parkinson's disease and multiple system atrophy) or with neuronal intranuclear inclusions in triplet repeat disorders (Huntington's disease and dentatorubral-pallidoluysian atrophy). A co-immunoprecipitation assay indicated that ERBB4 can interact with tau intracellularly. Notably, in corticobasal degeneration, we observed ectopic ERBB4 expression in astrocytes lacking apparent phosphorylated tau aggregates. These findings suggest a potential role for ERBB4 in the pathophysiology of tau-related neurodegenerative diseases.
Publicações recentes
Long-term efficacy and disease-specific responsiveness to protirelin in patients with spinocerebellar degeneration: A retrospective study.
[Trinucleotide repeat disorders].
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review.
Reduced Dopamine Transporter Uptake in Dentatorubral-Pallidoluysian Atrophy.
📚 EuropePMC201 artigos no totalmostrando 123
Long-term efficacy and disease-specific responsiveness to protirelin in patients with spinocerebellar degeneration: A retrospective study.
Parkinsonism & related disorders[Trinucleotide repeat disorders].
Radiologie (Heidelberg, Germany)Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
Molecular therapy. Nucleic acidsHereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review.
International journal of molecular sciencesReduced Dopamine Transporter Uptake in Dentatorubral-Pallidoluysian Atrophy.
Movement disorders clinical practiceDisrupted Transcriptional Networks in Mammalian Cells Stably Over-Expressing Pathogenic Atrophin-1.
Journal of neuroscience researchERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.
Neurochemistry internationalEpilepsy in dentatorubral-pallidoluysian atrophy: A systematic review and meta-analysis.
EpilepsiaChallenges in Polyglutamine Diseases: From Dysfunctional Neuronal Circuitries to Neuron-Specific CAG Repeat Instability.
International journal of molecular sciencesThe genetic landscape of spinocerebellar ataxias in Taiwan: Insights from 876 genetically confirmed cases.
Parkinsonism & related disordersDisrupted Transcriptional Networks by Mutant Atrophin-1 in a Cell Culture Model of Dentatorubral-Pallidoluysian Atrophy.
bioRxiv : the preprint server for biologyTotal corpus callosotomy for an adult patient with progressive myoclonic epilepsy associated with dentatorubral-pallidoluysian atrophy: illustrative case.
Journal of neurosurgery. Case lessonsIntrathecal baclofen therapy can improve spasticity associated with infantile-onset dentatorubral-pallidoluysian atrophy: illustrative cases.
Journal of neurosurgery. Case lessonsClinical and Genetic Findings in a Chinese Cohort of Dentatorubral-Pallidoluysian Atrophy Patients.
Annals of neurologyAccurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays.
Molecular neurobiology[Progressive Myoclonus Epilepsy: Diversity of Disorders and Key Points in Clinical Practice].
Brain and nerve = Shinkei kenkyu no shinpoApproach to Progressive Myoclonic Epilepsies: Clinical Clues for Genetic Testing.
Journal of child neurologyMRI-based brain structural changes in adult-onset dentatorubral-pallidoluysian atrophy.
NeuroradiologyThe analysis of schizophrenia-like psychosis in dentatorubral-pallidoluysian atrophy.
Frontiers in neurologyNatural History and Progression of Dentatorubral-Pallidoluysian Atrophy (DRPLA): A Retrospective Study of 22 Patients.
Movement disorders clinical practicePolyglutamine Ataxias in Denmark: Incidence and Relative Frequencies of SCA1, 2, 3, 6, 7, 17 and DRPLA in a Nationwide Cohort.
Cerebellum (London, England)Another common genetic ataxia in South Korea: Spinocerebellar ataxia 36.
European journal of human genetics : EJHGInsights into dentatorubral-pallidoluysian atrophy from a new Drosophila model of disease.
Neurobiology of diseaseMammalian nucleophagy: process and function.
AutophagyDentatorubral pallidoluysian atrophy with cognitive impairment, epilepsy, movement disorders, and psychosis - a case.
NeurocaseLocation of polyglutamine track affects pathogenic threshold of polyglutamine expansion diseases - Importance of association with the proteasome.
Biochemical and biophysical research communicationsDentatorubral-Pallidoluysian Atrophy (DRPLA) in Three Successive Generations with Anticipation in an Indian Family.
Annals of Indian Academy of NeurologyErucin, a Natural Isothiocyanate, Prevents Polyglutamine-Induced Toxicity in Caenorhabditis elegans via aak-2/AMPK and daf-16/FOXO Signaling.
International journal of molecular sciencesDentatorubral-pallidoluysian atrophy: a case report and review of literature.
Journal of medical case reportsIRF2BPL-Related Disorder, Causing Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) Is Characterized by Pathology Consistent with DRPLA.
Movement disorders : official journal of the Movement Disorder SocietyOverexpanded CAG repeats in ATN1 cause an Early-Onset Case of Dentatorubral-Pallidoluysian atrophy with novel phenotypes and a literature Review of Chinese patients.
GenePolyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
ACS chemical neuroscienceDentatorubral-pallidoluysian atrophy: a rare cause of epilepsy, ataxia and chorea.
Practical neurologyUnderstanding dentatorubral-pallidoluysian atrophy (DRPLA) symptoms and impacts on daily life: a qualitative interview study with patients and caregivers.
Therapeutic advances in rare diseaseAn Update on the Adult-Onset Hereditary Cerebellar Ataxias: Novel Genetic Causes and New Diagnostic Approaches.
Cerebellum (London, England)Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective.
Therapeutic advances in rare diseasePolyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects.
Proteomics[Progressive myoclonic epilepsy: a retrospective study of newly-diagnosed adult patients from a single center].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical geneticsDancing, Lurching and Swaying: An Indian Case of Dentatorubral-Pallidoluysian Atrophy.
Movement disorders clinical practiceDiagnostic uplift through the implementation of short tandem repeat analysis using exome sequencing.
European journal of human genetics : EJHGEarly-onset familial essential tremor is associated with nucleotide expansions of spinocerebellar ataxia in China.
Molecular biology reportsIntracerebral Distribution of CAG Repeat-Binding Small Molecule Visualized by Whole-Brain Imaging.
Bioconjugate chemistryPrevalence of repeat expansions causing autosomal dominant spinocerebellar ataxias in Hokkaido, the northernmost island of Japan.
Journal of human geneticsPolyQ Database-an integrated database on polyglutamine diseases.
Database : the journal of biological databases and curationInfantile-onset parkinsonism, dyskinesia, and developmental delay: do not forget polyglutamine defects!
Annals of clinical and translational neurologyIsolated paravermal T2 high-intensity lesions in dentatorubral-pallidoluysian atrophy.
Journal of the neurological sciencesNine Hereditary Movement Disorders First Described in Asia: Their History and Evolution.
Journal of movement disordersMachine Learning Approach for the Prediction of Age-Specific Probability of SCA3 and DRPLA by Survival Curve Analysis.
Neurology. GeneticsAtrophin-1 Function and Dysfunction in Dentatorubral-Pallidoluysian Atrophy.
Movement disorders : official journal of the Movement Disorder SocietyA Case of Congenital Hypotonia and Developmental Delay in an Individual with a De Novo Variant Outside of the Canonical HX-Motif of ATN1.
Case reports in geneticsDiagnostic Efficacy of Genetic Studies in a Series of Hereditary Cerebellar Ataxias in Eastern Spain.
Neurology. GeneticsCalpain-mediated proteolysis as driver and modulator of polyglutamine toxicity.
Frontiers in molecular neuroscienceCase report: Corneal endothelial degeneration and optic atrophy in dentatorubral-pallidoluysian atrophy quantified by specular micrography and optical coherence tomography.
Frontiers in neurologySimple and clear differentiation of spinocerebellar degenerations: Overview of macroscopic and low-power view findings.
Neuropathology : official journal of the Japanese Society of NeuropathologyUse of perampanel in children with refractory epilepsy of genetic aetiology.
Epileptic disorders : international epilepsy journal with videotapeThe neostriatum in polyglutamine diseases: preferential decreases in large neurons in dentatorubral-pallidoluysian atrophy and Machado-Joseph disease and in small neurons in Huntington disease.
Neuropathology : official journal of the Japanese Society of NeuropathologySingle-Tube Screen for Rapid Detection of Repeat Expansions in Seven Common Spinocerebellar Ataxias.
Clinical chemistryCAG repeat-binding small molecule improves motor coordination impairment in a mouse model of Dentatorubral-pallidoluysian atrophy.
Neurobiology of diseaseDRPLA: An unusual disease or an underestimated cause of ataxia in Brazil?
Parkinsonism & related disordersPeptide Based Therapy for Neurological Disorders.
Current protein & peptide sciencePallidal degenerations and related disorders: an update.
Journal of neural transmission (Vienna, Austria : 1996)Juvenile Huntington's Disease and Other PolyQ Diseases, Update on Neurodevelopmental Character and Comparative Bioinformatic Review of Transcriptomic and Proteomic Data.
Frontiers in cell and developmental biologyCHEDDA syndrome is an underrecognized neurodevelopmental disorder with a highly restricted ATN1 mutation spectrum.
Clinical geneticsThe rare and the common: An Austrian DRPLA family harboring the European haplotype.
Parkinsonism & related disordersSympathetic nerve outflow to skin in a case with dentatorubral-pallidoluysian atrophy.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of AustralasiaCoexistence of dentatorubral-pallidoluysian atrophy and Parkinson's disease: An autopsy case report.
Neuropathology : official journal of the Japanese Society of NeuropathologySGTA associates with intracellular aggregates in neurodegenerative diseases.
Molecular brainSelective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS.
Molecular therapy. Nucleic acidsDRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder.
Journal of neurologyClarification of undiagnosed ataxia using whole-exome sequencing with clinical implications.
Parkinsonism & related disordersEvidence and practices of the use of next generation sequencing in patients with undiagnosed autosomal dominant cerebellar ataxias: a review.
Arquivos de neuro-psiquiatriaThe cerebellar white matter lesions in dentatorubral-pallidoluysian atrophy.
Journal of the neurological sciencesAutophagy and Polyglutamine Disease.
Advances in experimental medicine and biologyArginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Brain : a journal of neurologyUniversal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression.
Molecular therapy. Nucleic acids[The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
Molekuliarnaia biologiiaApplication of protein knockdown strategy targeting β-sheet structure to multiple disease-associated polyglutamine proteins.
Bioorganic & medicinal chemistryThe largest caucasian kindred with dentatorubral-pallidoluysian atrophy: A founder mutation in italy.
Movement disorders : official journal of the Movement Disorder SocietyFat cadherins in mouse models of degenerative ataxias.
Scientific reportsPathogenesis of SCA3 and implications for other polyglutamine diseases.
Neurobiology of diseaseInvestigating PUM1 mutations in a Taiwanese cohort with cerebellar ataxia.
Parkinsonism & related disordersGeneration of human iPS cell line IBCHi001-A from dentatorubral-pallidoluysian atrophy patient's fibroblasts.
Stem cell researchDetection of dentate nuclei abnormality in a patient with dentatorubral-pallidoluysian atrophy using the quantitative susceptibility mapping.
Journal of the neurological sciences[Pathogenic gene variants and clinical phenotype features of 26 children with progressive myoclonic epilepsy].
Zhonghua er ke za zhi = Chinese journal of pediatricsCross-Sectional Area Analysis of the Head of the Caudate Nucleus in Huntington's Disease.
European neurologyDe Novo Variants Disrupting the HX Repeat Motif of ATN1 Cause a Recognizable Non-Progressive Neurocognitive Syndrome.
American journal of human geneticsPerampanel in lissencephaly-associated epilepsy.
Epilepsy & behavior case reportsThe Expanding Clinical Universe of Polyglutamine Disease.
The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatryDentatorubral-pallidoluysian Atrophy: An Update.
Tremor and other hyperkinetic movements (New York, N.Y.)Diverse mechanisms of autophagy dysregulation and their therapeutic implications: does the shoe fit?
AutophagyIdentifying SYNE1 ataxia and extending the mutational spectrum in Korea.
Parkinsonism & related disordersSuccessful treatment of psychosis in dentatorubral-pallidoluysian atrophy with quetiapine: A case report.
Neuropsychopharmacology reportsSpinocerebellar ataxia 27 with a novel nonsense variant (Lys177X) in FGF14.
European journal of medical geneticsTranscriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.
Frontiers in molecular neuroscienceSuccessful Treatment with Olanzapine of Psychosis in Dentatorubral-pallidoluysian Atrophy: A Case Report.
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of NeuropsychopharmacologyMultiple system atrophy and CAG repeat length: A genetic screening of polyglutamine disease genes in Italian patients.
Neuroscience lettersA diagnostic decision tree for adult cerebellar ataxia based on pontine magnetic resonance imaging.
Journal of the neurological sciencesPearls & Oy-sters: Family history of Huntington disease disguised a case of dentatorubral-pallidoluysian atrophy.
NeurologyThe CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
Handbook of clinical neurologyCo-expression Patterns between ATN1 and ATXN2 Coincide with Brain Regions Affected in Huntington's Disease.
Frontiers in molecular neuroscienceClinical and magnetic resonance imaging features of elderly onset dentatorubral-pallidoluysian atrophy.
Journal of neurologyStall in Canonical Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in Neurodegeneration.
Current biology : CBThe Missing Link in Polyglutamine Diseases.
Movement disorders clinical practiceRescue of ATXN3 neuronal toxicity in Caenorhabditiselegans by chemical modification of endoplasmic reticulum stress.
Disease models & mechanismsEfficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA).
Epilepsy & behavior case reportsCognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature.
Brain sciencesAtrophin controls developmental signaling pathways via interactions with Trithorax-like.
eLifeCommonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview.
Current Alzheimer researchDentatorubral-pallidoluysian atrophy (DRPLA) with a small ganglioglioma component containing neurofibrillary tangles and polyglutamine aggregation.
Neuropathology : official journal of the Japanese Society of NeuropathologyPeriodic Epileptiform Discharges in Children With Advanced Stages of Progressive Myoclonic Epilepsy.
Clinical EEG and neuroscienceSilencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs.
Acta biochimica PolonicaModulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Molecular neurobiologyIntroduction to the Special Issue on Spinal and Bulbar Muscular Atrophy.
Journal of molecular neuroscience : MNHuntington's Disease, Huntington's Disease Look-Alikes, and Benign Hereditary Chorea: What's New?
Movement disorders clinical practicePhotosensitivity in a patient with C9orf72 repeat expansion.
Amyotrophic lateral sclerosis & frontotemporal degenerationStriatal glucose hypometabolism in preadolescent-onset dentatorubral-pallidoluysian atrophy.
Journal of the neurological sciencesSpinocerebellar ataxias in Venezuela: genetic epidemiology and their most likely ethnic descent.
Journal of human geneticsG protein-coupled receptor 26 immunoreactivity in intranuclear inclusions associated with polyglutamine and intranuclear inclusion body diseases.
Neuropathology : official journal of the Japanese Society of NeuropathologyStudying polyglutamine diseases in Drosophila.
Experimental neurologyEye of the Tiger Sign and Very Late Onset in Dentatorubral-Pallidoluysian Atrophy.
Movement disorders clinical practiceTransfer of genetic therapy across human populations: molecular targets for increasing patient coverage in repeat expansion diseases.
European journal of human genetics : EJHGThe first identified Central-Eastern European patient with genetically confirmed dentatorubral-pallidoluysian atrophy.
Ideggyogyaszati szemle[Successful treatment of epilepsy and circadian rhythm disturbance with levetiracetam in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)].
No to hattatsu = Brain and developmentAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Atrofia dentato-rubro-pálido-luisiana.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Atrofia dentato-rubro-pálido-luisiana
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA model.
- Hereditary Ataxias: From Pathogenesis and Clinical Features to Neuroimaging, Fluid, and Digital Biomarkers-A Scoping Review.
- Long-term efficacy and disease-specific responsiveness to protirelin in patients with spinocerebellar degeneration: A retrospective study.
- [Trinucleotide repeat disorders].
- ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies.
- Reduced Dopamine Transporter Uptake in Dentatorubral-Pallidoluysian Atrophy.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:101(Orphanet)
- OMIM OMIM:125370(OMIM)
- MONDO:0007435(MONDO)
- GARD:5643(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q2280285(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
